Clinical trial · Interventional
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (14)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| asparaginase | Drug | Asparaginase | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| daunorubicin hydrochloride | Drug | Daunorubicin | ALIAS |
| dexamethasone | Drug | Dexamethasone | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| mercaptopurine | Drug | Mercaptopurine | ALIAS |
| methotrexate | Drug | Methotrexate | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of doxorubicin hydrochloride
- measure
- Reduce therapy in low-risk patients without loss of efficacy
- measure
- Reduce neurological complications
- measure
- Reduce allergic reactions against asparaginase
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosed with acute B-precursor or T-cell acute lymphoblastic leukemia (ALL)
* Meets 1 of the following risk criteria:
* Low-risk disease, defined by any of the following:
* WBC \< 25/nL
* B-precursor ALL
* Excluding pro-B ALL
* High-risk disease, defined by any of the following:
* WBC ≥ 25/nL
* T-cell ALL or pro-B ALL
* Chromosomal translocation 4/11
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* More than 7 days since prior therapy with steroids, vincristine, or daunorubicin hydrochloride
* More than 7 days since prior cytotoxic therapyReferences
Publications (0)
Data not yet available